HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reduced animal toxicity test revisions released

This article was originally published in The Rose Sheet

Executive Summary

Interagency Center for the Evaluation of Alternative Toxicological Methods seeking public comment on its report on the revised Up-and-Down Procedure of acute oral toxicity testing in animals, National Institute for Environmental Health Sciences announces in Feb. 7 Federal Register notice. Comment deadline is March 25. Available on 1ICCVAM's Web site, the report includes scientific peer review of revised UDP and final test guidelines and will be transmitted to U.S. federal agencies following comment period. ICCVAM reviewed the procedure, an alternative to conventional means of evaluating LD50, in an October report (2"The Rose Sheet" Oct. 15, 2001, p. 9). UDP uses fewer animals than conventional methods...

You may also be interested in...



OECD Alternative Methods To Replace Existing Animal Test

The Organisation for Economic Co-operation and Development, the international group charged with finding alternatives to animal tests, plans to eliminate animal test TG 401 and replace it with a revised Up-and-Down Procedure (TG 425) and two other testing methods in July, the National Toxicology Program Advisory Committee on Alternative Toxicological Methods said Nov. 28.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel